ClinicalTrials.gov Search Results 04/07/2020

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 1 | [A Phase I/II Study of Oblimersen Plus Cisplatin and](https://ClinicalTrials.gov/show/NCT00064259) [Fluorouracil in Gastric & Esophageal Junction Cancer](https://ClinicalTrials.gov/show/NCT00064259) | Terminated | Has Results | * Adenocarcinoma of the Esophagus * Adenocarcinoma of the Gastroesophageal Junction * Diffuse Adenocarcinoma of the Stomach * Intestinal Adenocarcinoma of the Stomach * Mixed Adenocarcinoma of the Stomach * Recurrent Esophageal Cancer * Recurrent Gastric Cancer * Squamous Cell Carcinoma of the Esophagus * Stage III Esophageal Cancer * Stage IIIA Gastric Cancer * and 4 more | * Biological: oblimersen sodium * Drug: cisplatin * Drug: fluorouracil | * Montefiore Medical Center, Bronx, New York, United States |
| 2 | [Pharmacokinetic Study of Genasense in Subjects With](https://ClinicalTrials.gov/show/NCT00543075) [Normal Renal Function, Mildly Impaired Renal Function, and](https://ClinicalTrials.gov/show/NCT00543075) [Moderately Impaired Renal Function](https://ClinicalTrials.gov/show/NCT00543075) | Completed | No Results Available | * Normal Renal Function * Mildly Impaired Renal Function * Moderately Impaired Renal Function | * Drug: Genasense (oblimersen, G3139) | * DaVita Clinical Research, Minneapolis, Minnesota, United States |
| 3 | [Rituximab and Oblimersen in Treating Patients With Stage II,](https://ClinicalTrials.gov/show/NCT00301795) [Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma](https://ClinicalTrials.gov/show/NCT00301795) | Terminated | No Results Available | * Stage III Grade 1 Follicular Lymphoma * Stage III Grade 2 Follicular Lymphoma * Stage III Grade 3 Follicular Lymphoma * Stage IV Grade 1 Follicular Lymphoma * Stage IV Grade 2 Follicular Lymphoma * Stage IV Grade 3 Follicular Lymphoma | * Biological: oblimersen sodium * Biological: rituximab * Other: laboratory biomarker analysis | * Cancer and Leukemia Group B, Chicago, Illinois, United States |
| 4 | [Pharmacokinetics of G3139 in Subjects With Advanced](https://ClinicalTrials.gov/show/NCT00543205) [Melanoma, Including Those With Normal Hepatic Function](https://ClinicalTrials.gov/show/NCT00543205) [and Those With Moderate Hepatic Impairment](https://ClinicalTrials.gov/show/NCT00543205) | Terminated | No Results Available | * Advanced Melanoma and Normal or Impaired * Hepatic Function | * Drug: Genasense® (G3139, oblimersen sodium) |  |
| 5 | [Oblimersen in Treating Patients With Relapsed or Refractory](https://ClinicalTrials.gov/show/NCT00062244) [Waldenstrom's Macroglobulinemia](https://ClinicalTrials.gov/show/NCT00062244) | Completed | No Results Available | * Waldenström Macroglobulinemia | * Biological: oblimersen sodium | * Mayo Clinic in Arizona, Scottsdale, Arizona, United States * Howard University Hospital, Washington, District of Columbia, United States * Mayo Clinic in Florida, Jacksonville, Florida, United States * University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States * Johns Hopkins University, Baltimore, Maryland, United States * Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States * Mayo Clinic, Rochester, Minnesota, United States * University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States |
| 6 | [Genasense as a 2-hour Intravenous Infusion in Subjects With](https://ClinicalTrials.gov/show/NCT00636545) [Solid Tumors](https://ClinicalTrials.gov/show/NCT00636545) | Completed | No Results Available | * Solid Tumors | * Drug: Oblimersen (Genasense) | * South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 7 | [Combination Chemotherapy Plus Oblimersen in Treating](https://ClinicalTrials.gov/show/NCT00017251) [Patients With Previously Untreated Extensive-Stage Small](https://ClinicalTrials.gov/show/NCT00017251) [Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00017251) | Completed | No Results Available | * Extensive Stage Small Cell Lung Cancer | * Biological: oblimersen sodium * Drug: carboplatin * Drug: etoposide * Other: pharmacological study * Other: laboratory biomarker analysis | * University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States |
| 8 | [Oblimersen in Treating Patients With Merkel Cell Carcinoma](https://ClinicalTrials.gov/show/NCT00079131) | Completed | No Results Available | * Recurrent Neuroendocrine Carcinoma of the Skin * Stage I Neuroendocrine Carcinoma of the Skin * Stage II Neuroendocrine Carcinoma of the Skin * Stage III Neuroendocrine Carcinoma of the Skin * Stage IV Neuroendocrine Carcinoma of the Skin | * Biological: oblimersen sodium * Other: pharmacological study * Other: laboratory biomarker analysis | * Memorial Sloan-Kettering Cancer Center, New York, New York, United States |
| 9 | [Genasense, Carboplatin, Paclitaxel (GCP) Combination in](https://ClinicalTrials.gov/show/NCT01200342) [Uveal Melanoma](https://ClinicalTrials.gov/show/NCT01200342) | Terminated | Has Results | * Melanoma | * Drug: Genasense * Drug: Paclitaxel * Drug: Carboplatin | * UT MD Anderson Cancer Center, Houston, Texas, United States |
| 10 | [Oblimersen and Gemcitabine in Treating Patients With](https://ClinicalTrials.gov/show/NCT00060112) [Advanced Solid Tumor or Lymphoma](https://ClinicalTrials.gov/show/NCT00060112) | Terminated | No Results Available | * Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue * Nodal Marginal Zone B-cell Lymphoma * Recurrent Adult Burkitt Lymphoma * Recurrent Adult Diffuse Large Cell Lymphoma * Recurrent Adult Diffuse Mixed Cell Lymphoma * Recurrent Adult Diffuse Small Cleaved Cell Lymphoma * Recurrent Adult Hodgkin Lymphoma * Recurrent Adult Immunoblastic Large Cell Lymphoma * Recurrent Adult Lymphoblastic Lymphoma * Recurrent Adult T-cell Leukemia/ Lymphoma * and 24 more | * Biological: oblimersen sodium * Drug: gemcitabine hydrochloride * Other: pharmacological study * Other: laboratory biomarker analysis | * Stanford University, Stanford, California, United States |
| 11 | [Oblimersen and Imatinib Mesylate in Treating Patients With](https://ClinicalTrials.gov/show/NCT00091078) [Advanced Gastrointestinal Stromal Tumors That Cannot Be](https://ClinicalTrials.gov/show/NCT00091078) [Removed By Surgery](https://ClinicalTrials.gov/show/NCT00091078) | Terminated | No Results Available | * Gastrointestinal Stromal Tumor | * Biological: oblimersen sodium * Drug: imatinib mesylate * Other: laboratory biomarker analysis | * M D Anderson Cancer Center, Houston, Texas, United States |
| 12 | [Oblimersen and Imatinib Mesylate in Treating Patients With](https://ClinicalTrials.gov/show/NCT00049192) [Chronic Myelogenous Leukemia](https://ClinicalTrials.gov/show/NCT00049192) | Completed | No Results Available | * Chronic Myelogenous Leukemia, BCR- ABL1 Positive * Chronic Phase Chronic Myelogenous Leukemia * Relapsing Chronic Myelogenous Leukemia | * Biological: oblimersen sodium * Drug: imatinib mesylate * Other: laboratory biomarker analysis | * Cancer and Leukemia Group B, Chicago, Illinois, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 13 | [Combination Chemotherapy Plus Oblimersen in Treating](https://ClinicalTrials.gov/show/NCT00054548) [Patients With Advanced Solid Tumors](https://ClinicalTrials.gov/show/NCT00054548) | Completed | No Results Available | * Unspecified Adult Solid Tumor, Protocol Specific | * Biological: oblimersen sodium * Drug: paclitaxel * Other: laboratory biomarker analysis * Other: pharmacological study | * University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States |
| 14 | [Carboplatin and Etoposide With or Without Oblimersen](https://ClinicalTrials.gov/show/NCT00042978) [Sodium in Treating Patients With Extensive Stage Small Cell](https://ClinicalTrials.gov/show/NCT00042978) [Lung Cancer](https://ClinicalTrials.gov/show/NCT00042978) | Completed | No Results Available | * Extensive Stage Small Cell Lung Cancer * Recurrent Small Cell Lung Cancer | * Biological: oblimersen sodium * Drug: carboplatin * Drug: etoposide | * Cancer and Leukemia Group B, Chicago, Illinois, United States |
| 15 | [Genasense® (Oblimersen Sodium), Fludarabine, and](https://ClinicalTrials.gov/show/NCT00078234) [Rituximab in Subjects With Chronic Lymphocytic Leukemia](https://ClinicalTrials.gov/show/NCT00078234) | Completed | No Results Available | * Chronic Lymphocytic Leukemia | * Drug: Oblimersen-rituximab-fludarabine | * Georgetown University Medical Center/Lombardi Cancer Center, Washington, District of Columbia, United States * Roswell Park Cancer Institute, Buffalo, New York, United States * Long Island Jewish Medical Center, New Hyde Park, New York, United States |
| 16 | [Oblimersen Sodium and Rituximab in Treating Patients With](https://ClinicalTrials.gov/show/NCT00054639) [Recurrent B-cell Non-Hodgkin Lymphoma](https://ClinicalTrials.gov/show/NCT00054639) | Completed | Has Results | * Cutaneous B-cell Non-Hodgkin Lymphoma * Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue * Intraocular Lymphoma * Nodal Marginal Zone B-cell Lymphoma * Recurrent Adult Burkitt Lymphoma * Recurrent Adult Diffuse Large Cell Lymphoma * Recurrent Adult Diffuse Mixed Cell Lymphoma * Recurrent Adult Diffuse Small Cleaved Cell Lymphoma * Recurrent Adult Grade III Lymphomatoid Granulomatosis * Recurrent Adult Immunoblastic Large Cell Lymphoma * and 11 more | * Biological: oblimersen sodium * Biological: rituximab * Other: laboratory biomarker analysis | * M D Anderson Cancer Center, Houston, Texas, United States |
| 17 | [Oblimersen and Interferon Alfa in Treating Patients With](https://ClinicalTrials.gov/show/NCT00059813) [Metastatic Renal Cell Cancer](https://ClinicalTrials.gov/show/NCT00059813) | Completed | No Results Available | * Recurrent Renal Cell Cancer * Stage IV Renal Cell Cancer | * Biological: recombinant interferon alfa * Biological: oblimersen sodium * Other: pharmacological study | * City of Hope, Duarte, California, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 18 | [Trial of Dacarbazine With or Without Genasense in Advanced](https://ClinicalTrials.gov/show/NCT00518895) [Melanoma](https://ClinicalTrials.gov/show/NCT00518895) | Completed | No Results Available | * Melanoma | * Drug: dacarbazine plus Genasense * Drug: dacarbazine plus placebo | * University of South Alabama Hospital, Mitchell Cancer Institute, Mobile, Alabama, United States * San Diego Pacific Oncology and Hematology Associates Inc., Encinitas, California, United States * Redwood Regional Medical Group, Inc., Santa Rosa, California, United States * Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States * Dana Farber Cancer Institute, Boston, Massachusetts, United States * Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States * Morristown Memorial - Atlantic Healthcare System, Morristown, New Jersey, United States * Cancer Care Associates, Oklahoma City, Oklahoma, United States * Cancer Care Associates, Site 1, Tulsa, Oklahoma, United States * St. Luke's Cancer Center, Bethlehem, Pennsylvania, United States * and 67 more |
| 19 | [Oblimersen Plus Doxorubicin and Docetaxel in Treating](https://ClinicalTrials.gov/show/NCT00063934) [Patients With Metastatic or Locally Advanced Breast Cancer](https://ClinicalTrials.gov/show/NCT00063934) | Terminated | Has Results | * Male Breast Cancer * Stage IIIA Breast Cancer * Stage IIIB Breast Cancer * Stage IIIC Breast Cancer * Stage IV Breast Cancer | * Biological: oblimersen sodium * Drug: doxorubicin hydrochloride * Drug: docetaxel * Biological: filgrastim * Biological: pegfilgrastim * Procedure: therapeutic conventional surgery * Other: pharmacological study * Other: laboratory biomarker analysis | * M D Anderson Cancer Center, Houston, Texas, United States |
| 20 | [Oblimersen, Cytarabine, and Daunorubicin in Treating Older](https://ClinicalTrials.gov/show/NCT00039117) [Patients With Acute Myeloid Leukemia](https://ClinicalTrials.gov/show/NCT00039117) | Completed | No Results Available | * Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities * Adult Acute Myeloid Leukemia With Inv(16) (p13;q22) * Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) * Adult Acute Myeloid Leukemia With t(8;21) (q22;q22) * Secondary Acute Myeloid Leukemia * Untreated Adult Acute Myeloid Leukemia | * Biological: oblimersen sodium * Drug: cytarabine * Drug: daunorubicin hydrochloride * Other: laboratory biomarker analysis * Other: pharmacological study | * Ohio State University Medical Center, Columbus, Ohio, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 21 | [Daunorubicin Hydrochloride, Cytarabine and Oblimersen](https://ClinicalTrials.gov/show/NCT00085124) [Sodium in Treating Patients With Previously Untreated Acute](https://ClinicalTrials.gov/show/NCT00085124) [Myeloid Leukemia](https://ClinicalTrials.gov/show/NCT00085124) | Completed | No Results Available | * Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities * Adult Acute Myeloid Leukemia With Inv(16) (p13;q22) * Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) * Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) * Adult Acute Myeloid Leukemia With t(8;21) (q22;q22) * Secondary Acute Myeloid Leukemia * Untreated Adult Acute Myeloid Leukemia | * Biological: oblimersen sodium * Drug: cytarabine * Drug: daunorubicin hydrochloride * Other: laboratory biomarker analysis | * Cancer and Leukemia Group B, Chicago, Illinois, United States * Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States |
| 22 | [Oblimersen and Doxorubicin in Treating Patients With](https://ClinicalTrials.gov/show/NCT00047229) [Advanced Hepatocellular Carcinoma (Liver Cancer)](https://ClinicalTrials.gov/show/NCT00047229) | Completed | No Results Available | * Liver Cancer | * Biological: oblimersen sodium * Drug: doxorubicin hydrochloride | * British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada * London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada * Princess Margaret Hospital, Toronto, Ontario, Canada |
| 23 | [This Study is Being Performed to Evaluate the Effect of](https://ClinicalTrials.gov/show/NCT00517218) [Genasense on the Efficacy and the Safety of Rituximab/](https://ClinicalTrials.gov/show/NCT00517218) [Fludarabine Combination Treatment in Previously Untreated](https://ClinicalTrials.gov/show/NCT00517218) [Subjects With Chronic Lymphocyctic Leukemia(CLL)](https://ClinicalTrials.gov/show/NCT00517218) | Withdrawn | No Results Available | * Lymphocytic Leukemia | * Drug: Genasense® (, oblimersen sodium G3139) |  |
| 24 | [Abraxane and Temodar Plus Genasense in Advanced](https://ClinicalTrials.gov/show/NCT00409383) [Melanoma](https://ClinicalTrials.gov/show/NCT00409383) | Unknown status | No Results Available | * Melanoma | * Drug: Genasense® (oblimersen) * Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension) * Drug: Temodar® (temozolomide) | * New York University Cancer Center, New York, New York, United States |
| 25 | [Docetaxel With or Without Oblimersen in Treating Patients](https://ClinicalTrials.gov/show/NCT00085228) [With Hormone-Refractory Adenocarcinoma (Cancer) of the](https://ClinicalTrials.gov/show/NCT00085228) [Prostate](https://ClinicalTrials.gov/show/NCT00085228) | Completed | No Results Available | * Prostate Cancer | * Biological: oblimersen sodium * Drug: docetaxel | * Kaiser Franz Josef Hospital, Vienna, Austria * Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium * Institut Jules Bordet, Brussels, Belgium * Cliniques Universitaires Saint-Luc, Brussels, Belgium * Universitair Ziekenhuis Gent, Ghent, Belgium * U.Z. Gasthuisberg, Leuven, Belgium * Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark * CHU de Grenoble - Hopital de la Tronche, Grenoble, France * Assaf Harofeh Medical Center, Zerifin, Israel * Ospedale S. Camillo-Forlanini, Rome, Italy * and 6 more |
| 26 | [Oblimersen and Dacarbazine in Treating Patients With](https://ClinicalTrials.gov/show/NCT00070343) [Advanced Malignant Melanoma That Has Responded to](https://ClinicalTrials.gov/show/NCT00070343) [Treatment on Clinical Trial GENTA-GM301](https://ClinicalTrials.gov/show/NCT00070343) | Unknown status | No Results Available | * Melanoma (Skin) | * Biological: oblimersen sodium * Drug: dacarbazine | * Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States |
| 27 | [A Phase I, Randomized, Open-label, Cross-over,](https://ClinicalTrials.gov/show/NCT00542893) [Pharmacokinetic Study of Genasense With and Without](https://ClinicalTrials.gov/show/NCT00542893) [Dacarbazine](https://ClinicalTrials.gov/show/NCT00542893) | Completed | No Results Available | * Advanced Melanoma | * Drug: Genasense® (G3139, oblimersen sodium) * Drug: Genasense followed by DTIC; then DTIC alone * Drug: DTIC alone; then Genasense followed by DTIC |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 28 | [Dacarbazine With or Without Oblimersen (G3139) in Treating](https://ClinicalTrials.gov/show/NCT00016263) [Patients With Advanced Malignant Melanoma](https://ClinicalTrials.gov/show/NCT00016263) | Completed | No Results Available | * Melanoma (Skin) | * Biological: oblimersen sodium * Drug: dacarbazine | * Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States * Genta Incorporated, Berkeley Heights, New Jersey, United States |
| 29 | [Oblimersen and Gemtuzumab Ozogamicin in Treating Older](https://ClinicalTrials.gov/show/NCT00017589) [Patients With Relapsed Acute Myeloid Leukemia](https://ClinicalTrials.gov/show/NCT00017589) | Completed | No Results Available | * Leukemia | * Biological: oblimersen sodium * Drug: gemtuzumab ozogamicin | * Genta Incorporated, Berkeley Heights, New Jersey, United States |
| 30 | [Oblimersen Plus Combination Chemotherapy and](https://ClinicalTrials.gov/show/NCT00039481) [Dexrazoxane in Treating Children and Adolescents With](https://ClinicalTrials.gov/show/NCT00039481) [Relapsed or Refractory Solid Tumors](https://ClinicalTrials.gov/show/NCT00039481) | Completed | No Results Available | * Cardiac Toxicity * Unspecified Childhood Solid Tumor, Protocol Specific | * Biological: oblimersen sodium * Drug: dexrazoxane hydrochloride * Drug: doxorubicin hydrochloride * Drug: cyclophosphamide * Biological: filgrastim * Other: laboratory biomarker analysis * Other: pharmacological study | * Children's Oncology Group, Arcadia, California, United States |
| 31 | [Docetaxel With or Without Oblimersen in Treating Patients](https://ClinicalTrials.gov/show/NCT00030641) [With Non-Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00030641) | Unknown status | No Results Available | * Lung Cancer | * Biological: oblimersen sodium * Drug: docetaxel | * University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States * Montgomery Cancer Center, Montgomery, Alabama, United States * Little Rock Hematology-Oncology Associates, Little Rock, Arkansas, United States * East Bay Medical Oncology, Concord, California, United States * Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States * Medical Oncology Care Associates, Orange, California, United States * Pacific Hematology/Oncology, San Francisco, California, United States * John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, United States * University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States * Whittingham Cancer Center, Norwalk, Connecticut, United States * and 34 more |
| 32 | [Dexamethasone With or Without Oblimersen in Treating](https://ClinicalTrials.gov/show/NCT00017602) [Patients With Relapsed or Refractory Multiple Myeloma](https://ClinicalTrials.gov/show/NCT00017602) | Completed | No Results Available | * Multiple Myeloma and Plasma Cell Neoplasm | * Biological: oblimersen sodium * Drug: dexamethasone | * Genta Incorporated, Berkeley Heights, New Jersey, United States |
| 33 | [A Phase I Study of G3139 Subcutaneous in Solid Tumors](https://ClinicalTrials.gov/show/NCT00543231) | Completed | No Results Available | * Tumors | * Drug: G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide | * Clinical Research Institute for Drug Development, San Antonio, Texas, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 34 | [Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in](https://ClinicalTrials.gov/show/NCT00005032) [Treating Patients With Recurrent Small Cell Lung Cancer](https://ClinicalTrials.gov/show/NCT00005032) | Completed | No Results Available | * Lung Cancer | * Biological: oblimersen sodium * Drug: paclitaxel | * University of Illinois at Chicago, Chicago, Illinois, United States * University of Chicago Cancer Research Center, Chicago, Illinois, United States * Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States * Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States * Evanston Northwestern Health Care, Evanston, Illinois, United States * Division of Hematology/Oncology, Park Ridge, Illinois, United States * Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States * Central Illinois Hematology Oncology Center, Springfield, Illinois, United States * Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States * Michiana Hematology/Oncology P.C., South Bend, Indiana, United States * Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States |
| 35 | [Phase I/II Study of Genasense in Patients With Chronic](https://ClinicalTrials.gov/show/NCT00021749) [Lymphocytic Leukemia](https://ClinicalTrials.gov/show/NCT00021749) | Completed | No Results Available | * Chronic Lymphocytic Leukemia * CLL | * Drug: Oblimerson sodium, G3139 | * Long Island Jewish Medical Center, New Hyde Park, New York, United States * MD Anderson Cancer Center, Houston, Texas, United States * San Antonio Cancer Institute, San Antonio, Texas, United States |
| 36 | [Combination Chemotherapy and Oblimersen in Treating](https://ClinicalTrials.gov/show/NCT00055822) [Patients With Advanced Colorectal Cancer](https://ClinicalTrials.gov/show/NCT00055822) | Completed | No Results Available | * Colorectal Cancer | * Biological: oblimersen sodium * Drug: fluorouracil * Drug: leucovorin calcium * Drug: oxaliplatin | * San Antonio Cancer Institute, San Antonio, Texas, United States |
| 37 | [Oblimersen, Thalidomide, and Dexamethasone in Treating](https://ClinicalTrials.gov/show/NCT00049374) [Patients With Relapsed or Refractory Multiple Myeloma](https://ClinicalTrials.gov/show/NCT00049374) | Completed | No Results Available | * Multiple Myeloma and Plasma Cell Neoplasm | * Biological: oblimersen sodium * Drug: dexamethasone * Drug: thalidomide | * Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States * St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States |
| 38 | [S0349 Rituximab, Cyclophosphamide, Doxorubicin,](https://ClinicalTrials.gov/show/NCT00080847) [Vincristine, and Prednisone With or Without Oblimersen in](https://ClinicalTrials.gov/show/NCT00080847) [Treating Patients With Advanced Diffuse Large B-Cell Non-](https://ClinicalTrials.gov/show/NCT00080847) [Hodgkin's Lymphoma](https://ClinicalTrials.gov/show/NCT00080847) | Terminated | No Results Available | * Contiguous Stage II Adult Diffuse Large Cell Lymphoma * Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma * Stage III Adult Diffuse Large Cell Lymphoma * Stage IV Adult Diffuse Large Cell Lymphoma | * Biological: oblimersen sodium * Biological: rituximab * Drug: cyclophosphamide * Drug: doxorubicin hydrochloride * Drug: vincristine sulfate * Drug: prednisone * Other: laboratory biomarker analysis | * Southwest Oncology Group, San Antonio, Texas, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 39 | [Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin,](https://ClinicalTrials.gov/show/NCT00070083) [Vincristine, and Prednisone in Treating Patients With Stage II,](https://ClinicalTrials.gov/show/NCT00070083) [Stage III, or Stage IV Diffuse Large B-Cell Lymphoma](https://ClinicalTrials.gov/show/NCT00070083) | Completed | No Results Available | * Lymphoma | * Biological: oblimersen sodium * Biological: rituximab * Drug: cyclophosphamide * Drug: doxorubicin hydrochloride * Drug: prednisone * Drug: vincristine sulfate | * Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States * British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada * Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey, British Columbia, Canada * British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada |
| 40 | [Fludarabine and Cyclophosphamide With or Without](https://ClinicalTrials.gov/show/NCT00024440) [Oblimersen in Treating Patients With Relapsed or Refractory](https://ClinicalTrials.gov/show/NCT00024440) [Chronic Lymphocytic Leukemia](https://ClinicalTrials.gov/show/NCT00024440) | Completed | No Results Available | * Leukemia | * Biological: filgrastim * Biological: oblimersen sodium * Drug: cyclophosphamide * Drug: fludarabine phosphate | * Genta Incorporated, Berkeley Heights, New Jersey, United States |
| 41 | [Oblimersen Sodium and Combination Chemotherapy in](https://ClinicalTrials.gov/show/NCT00736450) [Treating Patients With Newly Diagnosed Stage I, Stage II,](https://ClinicalTrials.gov/show/NCT00736450) [Stage III, or Stage IV Diffuse Large B-Cell Lymphoma](https://ClinicalTrials.gov/show/NCT00736450) | Terminated | Has Results | * Contiguous Stage II Adult Diffuse Large Cell Lymphoma * Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma * Stage I Adult Diffuse Large Cell Lymphoma * Stage III Adult Diffuse Large Cell Lymphoma * Stage IV Adult Diffuse Large Cell Lymphoma | * Biological: oblimersen sodium * Biological: rituximab * Drug: cyclophosphamide * Drug: doxorubicin hydrochloride * Drug: vincristine sulfate * Drug: prednisone * Procedure: biopsy * Genetic: microarray analysis * Other: immunohistochemistry staining method * Genetic: gene expression analysis * Genetic: cytogenetic analysis | * Saint Francis Medical Center, Grand Island, Nebraska, United States * UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States |
| 42 | [Oblimersen, Rituximab and Combination Chemotherapy in](https://ClinicalTrials.gov/show/NCT00086944) [Treating Patients With Relapsed or Refractory Aggressive](https://ClinicalTrials.gov/show/NCT00086944) [Non-Hodgkin's Lymphoma](https://ClinicalTrials.gov/show/NCT00086944) | Completed | No Results Available | * Recurrent Adult Diffuse Large Cell Lymphoma * Recurrent Grade 3 Follicular Lymphoma * Recurrent Mantle Cell Lymphoma | * Biological: oblimersen sodium * Biological: rituximab * Drug: ifosfamide * Drug: carboplatin * Drug: etoposide * Biological: filgrastim * Biological: pegfilgrastim * Other: laboratory biomarker analysis | * University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States |
| 43 | [Augmerosen Plus Fludarabine and Cytarabine in Treating](https://ClinicalTrials.gov/show/NCT00004862) [Patients With Refractory or Relapsed Acute Myeloid Leukemia](https://ClinicalTrials.gov/show/NCT00004862) [or Acute Lymphoblastic Leukemia](https://ClinicalTrials.gov/show/NCT00004862) | Completed | No Results Available | * Leukemia | * Biological: filgrastim * Biological: oblimersen sodium * Drug: cytarabine * Drug: fludarabine phosphate | * Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Title | Status | Study Results | Conditions | Interventions | Locations |
| 44 | [Chemotherapy in Treating Patients With Solid Tumors](https://ClinicalTrials.gov/show/NCT00003103) | Completed | No Results Available | * Bladder Cancer * Breast Cancer * Colorectal Cancer * Esophageal Cancer * Head and Neck Cancer * Kidney Cancer * Lung Cancer * Ovarian Cancer * Prostate Cancer * Unspecified Adult Solid Tumor, Protocol Specific | * Biological: oblimersen sodium * Drug: docetaxel | * Memorial Sloan-Kettering Cancer Center, New York, New York, United States |
| 45 | [Olimersen and Irinotecan in Treating Patients With Metastatic](https://ClinicalTrials.gov/show/NCT00004870) [or Recurrent Colorectal Cancer](https://ClinicalTrials.gov/show/NCT00004870) | Completed | No Results Available | * Colorectal Cancer | * Biological: oblimersen sodium * Drug: irinotecan hydrochloride | * Ireland Cancer Center, Cleveland, Ohio, United States * Brooke Army Medical Center, Fort Sam Houston, Texas, United States * San Antonio Cancer Institute, San Antonio, Texas, United States |

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services